We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East
Monthly Production Capacity: 1000kg
Packaging Information: 25kg/drum 1kg/bottle
Delivery Lead Time: 7 days after payment
Sample Provided: yes
Payment Terms: L/L
Product Information
Product name
Gliclazide
CAS No.
21187-98-4
Molecular Formula
C15H21N3O3S
Molecular Weight
323.4105
Quality Standard
99% up by HPLC, Medical Grade
Appearance
White powder
COA of Gliclazide
Item
Specification
Test Result
Characteristics
White or almost white powder
White powder
Solubility
Practically insoluble in water:
freely soluble in methylene chloride;
Sparingly soluble in acetone(96%); slightly soluble in alcohol (96%)
Conforms
M.P
162-166°C
164.0-164.5° C
Identification
Conform to the spectrum of the CRS Gliclazide
Conforms
Heavy metals
≤10ppm
<10ppm
Impurity B
≤2ppm
0.3ppm
Related substances
Impurity F ≤0.10%
<0.10%
Other single impurity ≤0.10%
<0.10%
Total of other impurities ≤0.2%
<0.13%
Loss on drying
≤0.25%
0.10%
Sulphated ash
≤0.1%
0.01%
Residual solvents
Ethyl acetate ≤0.5%
Below LOQ
Toluene ≤0.089%
Below LOQ
Assay (on dried basis)
99.0%-101.0%
99.5%
Conclusion
The Results Conforms With Enterprise Standards
Usage
Function of Gliclazide
Gliclazide is a second-generation sulfonylurea hypoglycemic drug, which is a secretion promoter. Its hypoglycemic mechanism is to selectively act on the β cells of the pancreatic islets to promote the secretion of insulin and increase the secretion of insulin after eating, so that the liver Glycogen production and output are inhibited, which is helpful for the prevention and treatment of diabetic microvascular disease. Gliclazide has a long and stable action time, and is generally used in elderly patients. Gliclazide is generally absorbed quickly after oral administration, reaching a peak in 3-4 hours, and 80% is excreted from the kidneys. If the kidney function is not good, attention should be paid. Less common side effects are gastrointestinal reactions, such as nausea and vomiting, and the incidence of hypoglycemia is less than that of other sulfonylureas. Gliclazide can be used alone or simultaneously with other hypoglycemic drugs. Its hypoglycemic level is practical and reliable, and it can be combined with biguanides, insulin sensitizers, DPP-4 inhibitors and insulin, and different combinations can be made according to different conditions of patients.